Investors Encouraged to Participate in Vistagen Securities Fraud Class Action

Vistagen's Securities Fraud Class Action: A Call to Investors

Overview

Investors in Vistagen Therapeutics, Inc. (NASDAQ: VTGN) are being urged by the Schall Law Firm to consider joining an ongoing class action lawsuit. This action arises from allegations of securities fraud that occurred between April 1, 2024, and December 16, 2025. The allegations involve claims that Vistagen made false and misleading statements regarding its drug candidate, fasedienol, particularly referencing the outcomes of its PALISADE-2 trial.

Context of the Class Action Lawsuit

The Schall Law Firm is known for representing shareholders and handling securities class action lawsuits across the nation. The firm emphasizes that if you purchased or otherwise acquired Vistagen securities during the specified class period, it’s crucial to act before the deadline of March 16, 2026. The lawsuit centers on claims that Vistagen provided investors with optimistic projections of the trial outcomes, which were later determined to be misleading. This information could have potentially inflated the stock price, leading to significant losses once the actual results became public.

Allegations Against Vistagen

According to the complaint filed, Vistagen allegedly misled the market by downplaying risks associated with the clinical studies of its fasedienol drug candidate. The results from PALISADE-2 trial were presented in a manner that suggested a strong likelihood of success while, in reality, they were less favorable than portrayed. As the truth emerged, investors found themselves suffering financial losses due to this misleading information.

The Importance of Joining the Lawsuit

By joining this class action, affected shareholders can potentially recover some of their lost funds. The Schall Law Firm encourages investors to contact them for further details about their rights and the lawsuit process. It’s crucial to understand that the class has not yet been certified; thus, current participants are not officially represented in legal terms until that happens.

How to Get Involved

Investors interested in learning more about participating in this lawsuit can reach out to the Schall Law Firm directly. Brian Schall, an attorney at the firm, has made himself available for consultations, emphasizing that inquiries can be made free of charge. Prospective class members can contact him at 310-301-3335 or visit www.schallfirm.com for additional information.

Conclusion

As the landscape of stock and securities becomes increasingly complex, being proactive about one’s investments is crucial. For Vistagen shareholders who have sustained losses, this class action lawsuit provides a pathway to seek accountability and potentially recover losses incurred due to alleged deceptive practices by Vistagen Therapeutics.

Investors should remember that taking no action leaves them as absent class members, without representation. Engaging with the legal process not only serves individual interests but also contributes to broader corporate accountability frameworks meant to protect shareholders from misleading corporate behaviors. Time is of the essence; interested investors are encouraged to take action immediately to align themselves with this class action opportunity.